Bone Biologics
Manufacturing · Massachusetts, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
2 Burlington Woods Dr Ste 100, Burlingto...Phone Number
(781) 552-4452Website
www.bonebiologics.comRevenue
-Stock Symbol
BBLGIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
2
1
1
1
1
About Bone Biologics
A publicly-held Biotechnology Company that is a spin off of the Musculoskeletal Transplant Foundation (MTF) using technology discovered and licensed from UCLA. Bone Biologics market and focus is in the Regenerative Medicine Orthobiologics space. Bone Biologics was founded in 2004 by University of California professors in collaboration with an Osaka University professor and a USC surgeon and acquired in 2006 by MTF as the major shareholder, who has been the primary funder since the acquisition. The Companys proprietary, patented platform technology UCB-1, exclusively licensed from UCLA, has met and surpassed existing standards of care outcomes in completed large animal model (sheep and Rhesus Monkey) studies that have demonstrated that the UCB-1 technology facilitates superior normal bone growth. The company believes that as a platform technology, UCB-1 has broad applications in delivering improved outcomes in almost all surgical procedures involved in bone repair and regeneration.Explore more
Bone Biologics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Bone Biologics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if Bone Biologics has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Bone Biologics, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Bone Biologics had a recent Job posting/layoffs
Product Launch: Get notified when Bone Biologics launches new products
Check out if Bone Biologics is spiking on competitors!
Funding: Get notified immidiatlly once Bone Biologics has new funding data
Earning: See what the market has to say on Bone Biologics recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Bone Biologics
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Compare Similar Companies to Bone Biologics
Compare insights from companies similar to Bone Biologics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Bone Biologics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Bone Biologics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Bone Biologics.
Bone Biologics financials insights
Gather financial insights about Bone Biologics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2014
Stock Offering
$16.1M
Bone Biologics Tech Stack
A closer look at the technologies used by Bone Biologics
Most Recent Scoops
Person-Based
Person-Based
Person-Based
Person-Based
Person-Based
Bone Biologics News & Media
Bone Biologics Highlights 2025 Key Operational, Scientific, and Corporate Milestones and Provides 2026 Outlook
Key accomplishments include expanded rhNELL-1 shelf life, advanced NB1 development, strengthened balance sheet, and maintained Nasdaq compliance Key accomplishments include expanded rhNELL-1 shelf life, advanced NB1 development, strengthened balance sheet, and maintained Nasdaq complianceBone Biologics Improves Extension of rhNELL-1 Product Shelf Life to 24 Months
Milestone advances manufacturing readiness and supports long-term commercialization strategy Milestone advances manufacturing readiness and supports long-term commercialization strategyBone Biologics Announces Pricing of $5.0 Million Public Offering - Business Wire
Bone Biologics Corporation (“Bone Biologics” or the “Company”) (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, today a...Bone Biologics Regains Compliance with Nasdaq Continued Listing Requirements
BURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (“Bone Biologics” or the “Company”) (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, today announced that it has received notice from The Nasdaq Stock Market LLC (“Nasdaq”) informing the Company that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) (the “Rule”) for continued listing on the Nasdaq Capital Market. Bone Biologics is now in compl
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Bone Biologics
Sign Up For FreeTo access detailed company insights
A publicly-held Biotechnology Company that is a spin off of the Musculoskeletal Transplant Foundation (MTF) using technology discovered and licensed from UCLA. Bone Biologics market and focus is in the Regenerative Medicine Orthobiologics space. Bone Biologics was founded in 2004 by University of California professors in collaboration with an Osaka... Read More
